-
The competition in the domestic ophthalmic anti-VEGF drug market is becoming more and more intense, and a number of products are already on the way
Time of Update: 2022-08-12
Click to enter the exhibition page Anti-VEGF drug is a monospecific antibody, which is characterized in that it can effectively inhibit the formation of new blood vessels and promote the regression of existing new blood vessels.
-
Hisco's wholly-owned subsidiary company Jupurui Zinc Granules passed the consistency evaluation of generic drugs
Time of Update: 2022-08-12
, has passed the consistency evaluation of generic drugs On May 25, Haisco issued an announcement saying that the wholly-owned subsidiary, Haisco Pharmaceutical (Meishan) Co.
The specification is 75mg The original research product of Polyprex Zinc Granules was developed by Japan ゼア Industry Co.
-
National Health Commission: China achieves full coverage of county and rural medical and health institutions
Time of Update: 2022-08-12
Talking about the positive progress and achievements in rural health undertakings, Zhu Hongming, deputy director of the grass-roots department and first-level inspector of the National Health Commission of China, said in Beijing on the 24th that by the end of 2021, there will be 23,000 county-level medical and health institutions nationwide, townships and villages.
-
A number of domestic class 1 new drugs, with annual sales exceeding 3 billion!
Time of Update: 2022-08-12
Specifically, Chia Tai Tianqing Pharmaceutical's Anlotinib Hydrochloride Capsules was approved for marketing in May 2018, and was included in the National Medical Insurance Category B catalog through negotiation in the same year, and 5 indications have been achieved so far .
-
Chinese medicine ushered in favorable policies again, which types of enterprises will benefit?
Time of Update: 2022-08-12
It is recommended to pay attention to the sound sales system, and the prescription Chinese patent medicine companies and the companies with differentiated advantages in the subdivision field that have the ability to research and develop innovative traditional Chinese medicines from theoretical research, new drug discovery and transformation, clinical trials, and evidence accumulation of evidence-based medicine.
-
Head to head!
Time of Update: 2022-08-12
FinishingLinanThe price of Lilly’s recently approved diabetes drug Mounjaro (tirzepatide) was exposed, with a monthly treatment price of about $974 (4 sticks), which is lower than Novo Nordisk’s weight loss drug Wegovy (semaglutide, GLP-1 receptor body agonist, 2.
-
The new trend of pharmacovigilance development, enterprises should change from passive response to active responsibility for drug safety
Time of Update: 2022-08-11
From the changes since the promulgation and implementation of the "Good Practice for Pharmacovigilance" (referred to as GVP) on May 1, 2021, we can see the development trend:Some time ago, the State Food and Drug Administration issued a notice on the "Guiding Principles of Pharmacovigilance Inspection" .
-
Comments on the Implementation Regulations of the Drug Administration Law (Draft for Comments) on Drug Production Article by Article
Time of Update: 2022-08-11
Staff Writer | Alang From | Dandelion (ouryao. com) On May 9, the State Food and Drug Administration issued the "Regulations on the Implementation of the Drug Administration Law of the People's Repub
-
Consistency Evaluation Approval Reshuffle
Time of Update: 2022-08-11
No reference preparation "grandfather medicine" As shown in Table 1, from the perspective of the elimination of the approval documents of the top 50 chemical drugs with the largest number of historical approvals, many of the top-ranked varieties have no reference preparations and cannot start the consistency evaluation .
-
Chia Tai Tianqing's Class 1 new drug is declared for listing today!
Time of Update: 2022-08-11
Click here to subscribe to the acceptance number and get the review updates as soon as possible From: CDE official website TQ-B3139 (CT-1139) is a c-Met/ALK/ROS multi-target tyrosine kinase inhibitor jointly developed by Chia Tai Tianqing and Shouyao Holding.
-
DRG/DIP reform will subvert the drug structure
Time of Update: 2022-08-11
Editor in charge : Yu Rujin Source: Editing Center Speaking of DRG/DIP, we must talk about the "Notice on Printing and Distributing the Three-Year Action Plan for the Reform of DRG/DIP Payment Methods" (Medical Insurance [2021] No. 48) issued by the National Medical Insurance Administration .
-
【Knowing Chen】Dongchen Pharmaceutical is not only a MCC manufacturer!
Time of Update: 2022-08-11
To this end, the market activities that Dongchen Pharmaceutical has organized or participated in over the years include: CPhI international exhibition, domestic API exhibition, promote domestic and independent microcrystalline cellulose brand to domestic and foreign customers; City-level technology promotion activities: Beijing , Shanghai, Guangzhou , Shijiazhuang, Shenzhen, Nanjing, Hangzhou, Jinan, Zhuhai, Chongqing, Yichang, Dalian, Tonghua, etc.
-
This pharmaceutical company completes tens of millions of dollars in financing for the development of first-in-class oncolytic bacteria products
Time of Update: 2022-08-11
Investment, the funds raised in this round of financing will be used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of SGN1, the world’s first tumor-targeted amino acid metabolic pathway-regulated oncolytic bacterial biological product, and to accelerate its globalization Clinical pipeline process .
-
With favorable policies, the domestic gene therapy market will usher in rapid growth!
Time of Update: 2022-08-11
The industry expects that with the acceleration of review and approval in China and the increase in the number of rare disease patients, the scale of clinical research in this field will continue to expand .
-
What is the outlook for the biosimilar market in the next decade?
Time of Update: 2022-08-11
At a regional level, Europe and North America are expected to remain the same in 2030, despite higher CAGRs of biosimilar usage (measured in PATDAY) in key Asian markets, Latin America and Southeast Asia, and Australasia over the next decade.
-
The "head market" continues to expand, with a "blue ocean" of over 80 billion yuan to be developed
Time of Update: 2022-08-11
Recently, Eli Lilly and Incyte jointly announced that the co-developed JAK inhibitor baricitinib showed excellent results in two phase III clinical studies, and the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supported the European Union Marketed for the treatment of adult patients with severe alopecia areata .
-
Roche launches 3 monkeypox virus rapid screening reagents, and more than 10 domestic pharmaceutical companies are deployed
Time of Update: 2022-08-11
Virus detection kit At the same time, more than 10 domestic biopharmaceutical companies, including Shuoshi Bio, Shengxiang Bio, Zhijiang Bio, Rejing Bio, and Huada Gene, also issued announcements one after another, saying that they have monkeypox virus monitoring reagent products or have developed monkeypox.
-
Can Luzsana become Hengrui's "Genentech"?
Time of Update: 2022-08-11
More than 250 clinical studies in each therapeutic area for global co-development and commercialization It is understood that through the partnership with the parent company Hengrui Medicine, Luzsana can evaluate and select assets from Hengrui's existing rich pipeline, covering oncology, cardiovascular, metabolism/diabetes, pain management, immunity, liver and kidney diseases, etc.
-
The promotion meeting of the special rectification work of drug safety was held
Time of Update: 2022-08-11
, sharing rectification experience around digging into clues of cases, strictly investigating major and important cases, improving the effectiveness of rectification, focusing on outstanding problems, strengthening mechanism construction, and innovating governance methods At the meeting, representatives of three key liaison units from Tianjin, Guangxi, and Sichuan (regional and municipal) Food and Drug Administration, Xuzhou Market Supervision Bureau of Jiangsu Province, Linyi City Market Supervision Bureau of Shandong Province, and Deqing County Government of Huzhou City, Zhejiang Province delivered speeches.
-
Blockbuster small molecule drugs officially announced the new crown treatment potential from 1 to 2 to take the new blue ocean
Time of Update: 2022-08-11
In this race against the new crown, another innovative pharmaceutical company, Ascentage Pharma (6855. HK), came to an end, bringing fresh blood and a turning point to this protracted battle . Because
